Evolent Health, Inc. Research and Development Expense
Evolent Health, Inc. (EVH) reported Research and Development Expense of $3.80 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-03
- Evolent Health, Inc. research and development expense for the quarter ending 2022-09-30 was $3.80M, a 9.52% decline year-over-year.
- Evolent Health, Inc. research and development expense for the quarter ending 2022-06-30 was $3.80M.
- Evolent Health, Inc. research and development expense for the quarter ending 2022-03-31 was $4.10M, a 20.59% increase year-over-year.
- Evolent Health, Inc. research and development expense for the quarter ending 2021-12-31 was $4.40M.
- Evolent Health, Inc. research and development expense for fiscal 2021 was $15.50M, a 2.65% increase from fiscal 2020.
- Evolent Health, Inc. research and development expense for fiscal 2020 was $15.10M, a 23.74% decline from fiscal 2019.
- Evolent Health, Inc. research and development expense for fiscal 2019 was $19.80M, a 8.79% increase from fiscal 2018.
- Evolent Health, Inc. research and development expense for fiscal 2018 was $18.20M, a 5.81% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $3.80M 10-Q · filed 2022-11-03 | $7.60M derived: sum of 2 quarters · filed 2022-11-03 | $11.70M 10-Q · filed 2022-11-03 | $16.10M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | $3.80M 10-Q · filed 2022-08-03 | $7.90M 10-Q · filed 2022-08-03 | $12.30M derived: sum of 3 quarters · filed 2022-08-03 | $16.50M derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-03-31 | $4.10M 10-Q · filed 2022-05-05 | $8.50M derived: sum of 2 quarters · filed 2022-05-05 | $12.70M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $8.60M derived: sum of 2 quarters · filed 2022-11-03 | $15.50M 10-K · filed 2022-02-24 | |
| 2021-09-30 | $4.20M 10-Q · filed 2022-11-03 | $11.10M 10-Q · filed 2022-11-03 | ||
| 2021-03-31 | $3.40M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $15.10M 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $19.80M 10-K · filed 2022-02-24 | |||
| 2018-12-31 | $18.20M 10-K · filed 2021-02-26 | |||
| 2017-12-31 | $17.20M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $11.10M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $5.00M derived: sum of 2 quarters · filed 2018-03-01 | $5.80M derived: sum of 3 quarters · filed 2018-03-01 | $5.80M 10-K · filed 2018-03-01 |
| 2015-09-30 | $2.50M 10-Q · filed 2015-11-06 | $3.30M derived: sum of 2 quarters · filed 2015-11-06 | $3.30M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $800.00K 10-Q · filed 2015-08-07 | $800.00K 10-Q · filed 2015-08-07 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-03-03 | |||
| 2013-12-31 | $2.00M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FRANKLIN COVEY CO (FC) | United States | $0.195B | 123.76 |
| GARTNER INC (IT) | United States | $11.326B | 11.20 |